Cargando…
Pooled Data Analysis of the Long-Term Treatment Effects of Tolvaptan in ADPKD
INTRODUCTION: In 1- and 3-year randomized trials, tolvaptan slowed kidney function decline in subjects with autosomal dominant polycystic kidney disease (ADPKD) at risk of rapid progression. The 3-year trial also evaluated effects on total kidney volume (TKV); slowing of TKV growth was demonstrated....
Autores principales: | Zhou, Xiaolei, Davenport, Eric, Ouyang, John, Hoke, Molly E., Garbinsky, Diana, Agarwal, Indra, Krasa, Holly B., Oberdhan, Dorothee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9091612/ https://www.ncbi.nlm.nih.gov/pubmed/35570988 http://dx.doi.org/10.1016/j.ekir.2022.02.009 |
Ejemplares similares
-
Tolvaptan and Kidney Function Decline in Older Individuals With Autosomal Dominant Polycystic Kidney Disease: A Pooled Analysis of Randomized Clinical Trials and Observational Studies
por: Chebib, Fouad T., et al.
Publicado: (2023) -
Effects of tolvaptan discontinuation in patients with autosomal dominant polycystic kidney disease: a post hoc pooled analysis
por: Lioudis, Michael, et al.
Publicado: (2023) -
A Randomized Trial of Modified-Release Versus Immediate-Release Tolvaptan in ADPKD
por: Perrone, Ronald D., et al.
Publicado: (2020) -
Long-Term Outcomes of Longitudinal Efficacy Study With Tolvaptan in ADPKD
por: Higashihara, Eiji, et al.
Publicado: (2021) -
Tolvaptan in ADPKD Patients With Very Low Kidney Function
por: Torres, Vicente E., et al.
Publicado: (2021)